The New York Stock Exchange helped ring in this year’s Fierce 15 by honoring the winners on the trading floor Monday morning.

Japan biotech xFOREST Therapeutics is teaming up with a drug discovery solutions provider in a research pact aiming to ...

Medtronic has received FDA approval for a new implant aimed at improving bladder control, with a small device placed near the ...

Nina Schor, M.D., Ph.D., will officially stop serving as head of the NIH’s Office of Intramural Research (OIR) on Sept. 30, ...

Momentum started building behind icotrokinra last year when J&J posted results from another phase 3 trial, dubbed Iconic-Lead, which saw 64.7% of treated patients achieve clear or almost clear skin at ...

The healthcare world is awash in data—medical device data, electronic patient records, public-health surveillance data, clinical data, wearable data, and more. | Five Key Data Management Questions for ...

Precision medicine is reshaping the landscape of clinical development, offering more advanced strategies to align therapies with individual biological variability. Recent research shows that drug ...

Medical device manufacturer Exactech has agreed to pay $8 million to settle allegations that it concealed defects in a popular line of artificial knee implants, which have been blamed for thousands | ...

Thousands of jobs at Baxter are potentially on the line as the medtech giant embarks on a cost-cutting plan in the wake of a year that CEO José Almeida said had “disappointed” the company. Alongside ...

Intuitive Surgical has received an FDA green light for the fifth generation of its multiport da Vinci robot, following more than a decade of research and development. The company said the da Vinci 5 ...

Artificial intelligence developer Owkin scored a major collaboration with Sanofi to help bring its digital clinical research platform to bear on the drugmaker’s core oncology efforts in four different ...

Last month, Fierce Biotech told you about an unknown number of layoffs due to hit Takeda as the Japanese pharma moves away from early-stage R&D work in adeno-associated virus-based gene therapies and ...